For the next quarter of 2012, cost of revenue, including eBioscience, was $24.4 million, when compared with $22.4 million in the same period of 2011. Item gross margin was 58 percent, as compared to 62 percent in the same period of 2011. Cost of providers and other was $3.3 million in comparison to $3.4 million in the same period of 2011. For the second one fourth of 2012, operating expenditures were $54.1 million, including acquisition-related nonrecurring costs of $4.7 million and a stock compensation charge of $8.3 million related to the acceleration of stock options held under eBioscience collateral incentive plans. This compared to operating expenses of $42.0 million in the same amount of 2011. ‘Through the second quarter we completed the acquisition of eBioscience which allows us to gain access to significant new marketplaces to operate a vehicle future growth and profitability,’ said Frank Witney, chief and president executive officer.AccessPharmacy helps meet needs of pharmacy education In five years, 300 nearly, 000 practicing pharmacists shall be needed nationwide to serve an aging population, a 30 % increase compared with 2002, according to the U.S. Section of Labor. To help meet this growing dependence on pharmacists, McGraw-Hill Professional, a respected global provider of details assets for the scientific and medical communities, has launched AccessPharmacy, an online content material solution, which is made to keep pace with the changing demands of pharmacy education.